
Company Description
Kindeva is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Manufacturing More Tomorrows™ for patients worldwide. We go beyond manufacturing to deliver strategic value through excellence in scalability and deep scientific expertise. Our comprehensive capabilities include Annex 1-compliant, state-of-the-art aseptic fill finish and next-generation sustainable inhalation propellant (NGP) technology. With proven expertise in pulmonary, nasal, dermal, and sterile injectable drug delivery, Kindeva partners with customers to meet today’s demands while delivering the possibilities of tomorrow.
Company Background
Kindeva brings 100+ years of drug delivery experience and has pioneered combination product technologies since 1956. Today the company has 2,000+ employees, ~1,300 patents and 75 inventions in use, and ships ~100 million commercial devices annually. Headquartered in Woodbury, Minnesota.
Facilities
10+ manufacturing and R&D sites with a ~1 million sq. ft. cGMP footprint: Woodbury, MN; Bridgeton, Brentwood and Maryland Heights, MO; Lexington, KY; Germantown, MD; Northridge and Union City, CA; Loughborough and Clitheroe, UK. Bridgeton offers 155,000+ sq. ft. of aseptic operations space with Annex 1-compliant fill lines.
Services and Capabilities
End-to-end CDMO services for drug-device combination products:
- Development: formulation and device development
- Manufacturing: clinical supply through commercial scale
- Sterile fill finish: vials, cartridges and prefilled syringes on high-speed, Annex 1-compliant isolator lines; technology transfer
- Analytical testing and characterization
- Regulatory support (FDA, EMA and global)
- Post-commercialization lifecycle management
Delivery expertise: sterile injectables and autoinjectors (TruJect™, BinaJect®, ComboPen®); pulmonary (pMDIs, breath-actuated inhalers, low-GWP green propellants); nasal; and dermal (transdermal patches, microneedle arrays).